Turkey Liver Diseases Therapeutics Market Analysis

Turkey Liver Diseases Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Turkey Liver Disease Therapeutics market will reach a value of $299 Mn from $185 Mn in 2022, growing at a CAGR of 6.2 % during 2022-2030. Liver Disease Therapeutics in Turkey is dominated by a few domestic pharmaceutical companies such as Abdi İbrahim, Mustafa Nevzat, and Deva Holding. The Liver Disease Therapeutics market in Turkey is segmented into different types of disease and different therapy types. Some of the major factors affecting the Turkey Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10TRPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Turkey AUTHOR: Dr. Vishwa Modhia

Buy Now

Turkey Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Turkey Liver Disease Therapeutics market will reach a value of $299 Mn from $185 Mn in 2022, growing at a CAGR of 6.2 % during 2022-2030.

Turkey is an upper middle-income, developing transcontinental country located in Southeastern Europe and Southwestern Asia bordering the Black Sea. Chronic viral hepatitis, particularly hepatitis B and C, is prevalent in Turkey. It is believed that approximately 4% of the Turkish population has chronic hepatitis B, while approximately 1% has chronic hepatitis C.

Turkey's healthcare system is not only economical but also of good quality. They are the region's top healthcare provider, providing inhabitants with the best care available. According to the latest WHO data published in 2020 Liver Disease Deaths in Turkey reached 6,340 or 1.63% of total deaths. The age-adjusted Death Rate is 7.14 per 100,000 population ranking Turkey 150th in the world. Turkey's government spent 4.6% of its GDP on healthcare in 2020.

Turkey Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Chronic liver disease patients may also be eligible for specialised care through the Turkish Society of Hepatology, which offers diagnostic tests, specialist consultations, and liver transplant services. The Turkish labour force is young and well-educated. Furthermore, Turkey benefits from a favourable geopolitical location as well as a swift economic recovery following COVID-19, which makes doing business easier. These aspects could boost Turkey's Liver Disease Therapeutics market.

Market Restraints

In Turkey, there is a need for better awareness and screening for liver disease. While there are no systematic screening programmes for liver disease, there are efforts underway to raise awareness of the condition and its risk factors. Turkey's manufacturing sector is heavily reliant on imports. These factors may deter new entrants into the Turkey Liver Disease Therapeutics market.

Competitive Landscape

Key Players

  • Abdi İbrahim: Abdi İbrahim is a Turkish pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
  • Mustafa Nevzat: Mustafa Nevzat is a Turkish pharmaceutical company that produces a variety of therapeutics, including those for liver disease
  • Deva Holding: Deva Holding is a Turkish pharmaceutical company that produces a range of therapeutic products, including those for liver disease
  • Acıbadem: Acıbadem İlaç is a Turkish pharmaceutical company that produces a variety of therapeutics, including those for liver disease

Healthcare Policies and Reimbursement Scenarios

In Turkey, the regulation and reimbursement of liver therapeutics are overseen by the Turkish Medicines and Medical Devices Agency (TMMDA) and the Social Security Institution (SSI), respectively. In terms of reimbursement, the SSI pays for qualifying patients' liver treatments. The SSI manages the reimbursement process, determining which therapies are eligible for reimbursement and the conditions under which they will be funded.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

  • Chemotherapy
  • Antiviral Drugs
  • Vaccines
  • Immunosuppressants
  • Corticosteroids
  • Immunoglobulins
  • Targeted Therapy

By Disease Type (Revenue, USD Billion):

  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Autoimmune Diseases
  • Cancer
  • Hepatitis
  • Genetic Disorder
  • Others

By Distribution Channel (Revenue, USD Billion):

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 29 March 2023
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up